Locoid
(Hydrocortisone Butyrate)ApprovedSmall molecule
Locoid is one of 24 small molecule programs targeting Granuloma. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
23
Competitors
8
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
35 competitors in Granuloma
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Rayos
RRoxane Laboratories
Approved
Compound Betamethasone
SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Approved
Enbrel
IImmunex
Phase 3
Nexium
DDexcel Pharma Technologies Ltd.
Phase 3
Zinbryta
RochePhase 2
Intron a
SanofiPhase 2
Olumiant
Eli LillyPhase 2
Orencia
Bristol-Myers SquibbPhase 2
Locoid
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Mar 31, 1982
LOCOID
NDA NDA018514
Oct 29, 1982
LOCOID
NDA NDA018652
Jan 7, 1983
LOCOID
NDA NDA018795
Jul 3, 1984
LOCOID
NDA NDA019106
Feb 25, 1987
LOCOID
NDA NDA019116
Sep 15, 1988
LOCOID
NDA NDA019819
Sep 8, 1997
LOCOID LIPOCREAM
NDA NDA020769
May 18, 2007
LOCOID
NDA NDA022076
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hydrocortisone Butyrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details